KR102488796B1 - 안구 건조증 치료 방법 - Google Patents

안구 건조증 치료 방법 Download PDF

Info

Publication number
KR102488796B1
KR102488796B1 KR1020197004640A KR20197004640A KR102488796B1 KR 102488796 B1 KR102488796 B1 KR 102488796B1 KR 1020197004640 A KR1020197004640 A KR 1020197004640A KR 20197004640 A KR20197004640 A KR 20197004640A KR 102488796 B1 KR102488796 B1 KR 102488796B1
Authority
KR
South Korea
Prior art keywords
composition
eye
subject
tear film
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197004640A
Other languages
English (en)
Korean (ko)
Other versions
KR20190031280A (ko
Inventor
양원석
강신욱
김경순
Original Assignee
리젠트리 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리젠트리 엘엘씨 filed Critical 리젠트리 엘엘씨
Publication of KR20190031280A publication Critical patent/KR20190031280A/ko
Application granted granted Critical
Publication of KR102488796B1 publication Critical patent/KR102488796B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020197004640A 2016-07-18 2017-07-17 안구 건조증 치료 방법 Active KR102488796B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,592 2016-07-18
US62/363,565 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (2)

Publication Number Publication Date
KR20190031280A KR20190031280A (ko) 2019-03-25
KR102488796B1 true KR102488796B1 (ko) 2023-01-13

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004640A Active KR102488796B1 (ko) 2016-07-18 2017-07-17 안구 건조증 치료 방법

Country Status (8)

Country Link
US (2) US10960051B2 (enExample)
EP (1) EP3484497A4 (enExample)
JP (1) JP6889771B2 (enExample)
KR (1) KR102488796B1 (enExample)
CN (1) CN109789182A (enExample)
AU (1) AU2017300268B2 (enExample)
CA (1) CA3031069A1 (enExample)
WO (1) WO2018017479A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012808A1 (en) 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
CN101195025A (zh) * 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
CA2458883C (en) * 2001-08-29 2017-11-28 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
JP2008526986A (ja) * 2005-01-13 2008-07-24 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 神経変性疾患、筋変性疾患または神経筋変性疾患による組織の変敗、傷害または損傷の治療方法または予防の方法あるいは前記疾患によって悪影響を受ける組織の修復方法
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
KR20080033939A (ko) * 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Also Published As

Publication number Publication date
US10960051B2 (en) 2021-03-30
US20190240294A1 (en) 2019-08-08
JP6889771B2 (ja) 2021-06-18
CN109789182A (zh) 2019-05-21
AU2017300268A1 (en) 2019-01-31
EP3484497A4 (en) 2020-01-01
JP2019525923A (ja) 2019-09-12
AU2017300268B2 (en) 2024-06-13
CA3031069A1 (en) 2018-01-25
KR20190031280A (ko) 2019-03-25
EP3484497A1 (en) 2019-05-22
WO2018017479A1 (en) 2018-01-25
US20210213103A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US10004785B2 (en) LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
US20090041855A1 (en) Therapeutic agent for ophthalmic diseases
US20210213103A1 (en) Methods of treating dry eye syndrome
US20170239330A1 (en) Formulations for histatin therapeutics
Kumagami et al. Comparison of Corneal Safety and Intraocular Pressure–Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions
Tu et al. Dry eye
EP3338792A1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
HK40012612A (en) Methods of treating dry eye syndrome
AU2023300970A1 (en) Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
US20110044970A1 (en) Pharmaceutical compositions and methods for the treatment of dry eye

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4